INTRODUCTION
============

Colorectal cancer (CRC) is the fourth most commonly diagnosed cancer and the second leading cause of cancer death in the United States for both sexes combined, with 136,800 new cancer cases and 50,300 deaths estimated in 2014.[@b1] Registry data from the past decade indicate that both disease incidence and mortality decreased by approximately 3% per year,[@b2] largely due to the increased use of screening.[@b3],[@b4] Despite the effectiveness of screening and the availability of various screening options, only 58% of US adults aged 50 to 75 years had received guideline-recommended testing in 2013.[@b5] Previous studies have demonstrated that a substantial percentage of CRC deaths are attributable to nonuse of screening.[@b6],[@b7] This rallied a recent initiative from the National Colorectal Cancer Roundtable (NCCR), a national coalition of public, private, and voluntary organizations, to aim for screening rates of 80% in the United States by 2018.[@b8] However, an estimate of the potential benefits of increasing uptake by an additional 22% in terms of the number of CRC cases and deaths averted is needed to inform public discourse and policy on this initiative and to project both the short-term and long-term public health "return on investment." In the current study, we used advanced modeling approaches to estimate the potential benefits in terms of new CRC cases and deaths averted from achieving the NCCR goal.

MATERIALS AND METHODS
=====================

The current study was based on men and women aged 50 to 100 years, and was simulated to match the 1980 through 2030 US population in terms of their life expectancy, risk of CRC, and past and future use of screening. The analyses used the Microsimulation Screening Analysis-Colon (MISCAN-COLON) model, which has been used to inform US Preventive Services Task Force screening recommendations.[@b9]

Microsimulation Model
---------------------

The MISCAN-COLON model is part of the Cancer Intervention and Surveillance Modeling Network (CISNET),[@b10] and has been described extensively elsewhere.[@b11] The model integrates the natural history of CRC, its heterogeneity, outcomes, and the effects of screening and treatment. The model allows for the flexible evaluation of various screening scenarios by leveraging observed data. The modeled effects of screening demonstrate good concordance with several randomized screening trials.[@b12]--[@b16]

Source Data
-----------

Demography estimates were obtained from the US Census Bureau.[@b17] Overall life expectancy was based on generational US life tables from the Berkeley Mortality Database.[@b18] Age-specific and size-specific prevalence of adenomas was based on autopsy and colonoscopy data from before the era of screening.[@b10] Age-, stage-, and location-specific cancer incidence was based on prescreening data (years 1975-1979) from the Surveillance, Epidemiology, and End Results program[@b19]; cancer survival was based on more recent Surveillance, Epidemiology, and End Results data (years 2000-2010).

Data regarding the historical use of colonoscopy, fecal occult blood tests, and sigmoidoscopy in the United States were derived from data from the 1987 through 2013 National Health Interview Survey (NHIS).[@b5] In 2013, 58% of the population aged 50 to 75 years reported being up-to-date on screening. The percentages that were up-to-date with each specific test were 54% for colonoscopy, 8% for fecal occult blood tests, and 4% for sigmoidoscopy.

Screening Scenarios
-------------------

In the current analysis, we evaluated a scenario in which the screening rate increased linearly from 58% in 2013 to 80% in 2018, with no further increase occurring through 2030. We compared this scenario to one in which screening rates remained constant at approximately 60%. We evaluated the magnitude of the reduction in CRC incidence and mortality rates per year during both short-term (2013-2020) and extended (2013-2030) follow-up. Screening consisted of a mix of colonoscopy, sigmoidoscopy, and fecal occult blood testing in accordance with estimates from the NHIS. Patients with a positive fecal occult blood test or sigmoidoscopy (for adenomas or cancer) were referred to diagnostic colonoscopy and patients in whom adenomas were detected were referred for colonoscopic surveillance according to guidelines from the US Multi-Society Task Force on Colorectal Cancer.[@b20] Patient adherence to diagnostic colonoscopy and surveillance colonoscopy was assumed to be 80%.[@b21],[@b22]

RESULTS
=======

Incidence Rates and Avoidable New Cancer Cases
----------------------------------------------

Under the assumption of approximately constant CRC screening levels in the United States between 2013 and 2030, the crude CRC incidence rate per 100,000 population per year would increase from 137 in the first year of follow-up (2014) to 149 in 2030 ([Fig. 1](#fig01){ref-type="fig"} *Top*) due to aging of the population. If screening uptake increased from 58% in 2013 to 80% in 2018, the incidence rates (per 100,000 population) would decrease from 164 in 2014 to 117 in 2030. Compared with a scenario of constant CRC screening levels, the goal of "80% by 2018" would initially increase CRC incidence rates by 20% in 2014 because of the early detection of CRC among previously unscreened individuals, but subsequently decrease the incidence rates by 17% by 2020 and by 22% by 2030. With the estimated population of individuals aged 50 to 100 years expected to increase from 108 million in 2014 to 133 million by 2030, the above effects on incidence and mortality rates would result in 43,000 averted cases per year by 2030, and a total of 277,000 cases averted from 2013 through 2030 (Table [1](#tbl1){ref-type="table"}).

![Crude colorectal cancer (*Top*) incidence and (*Bottom*) mortality rates in the US population aged ≥50 years, under 2 scenarios of screening uptake. In the first scenario, reported screening rates remained at a constant level of approximately 60% from 2013 through 2030, whereas in the other scenario, screening rates increased from 60% to 80% by 2018 and remained constant thereafter.](cncr0121-2281-f1){#fig01}

###### 

Difference in the Number of CRC Cases and Deaths Per Year When Achieving CRC Screening Rates of 80% in the United States by 2018, Compared With Constant Screening Rates of 60%

                                                Calendar Year                      
  --------------------------------------------- --------------- ----- ----- ------ ------
  Difference in no. of CRC cases (thousands)                                       
   Per year                                     29              27    −30   −38    −43
   Cumulative                                   29              141   28    −112   −277
  Difference in no. of CRC deaths (thousands)                                      
   Per year                                     −1              −7    −13   −18    −21
   Cumulative                                   −1              −17   −60   −123   −203

Abbreviation: CRC, colorectal cancer.

Mortality Rates and Avoidable Cancer Deaths
-------------------------------------------

There would be an immediate mortality benefit of increasing CRC screening rates to 80% by 2018. While the crude CRC mortality rate per 100,000 population would increase from 44 in 2014 to 48 in 2030 under constant screening levels of 60%, the mortality rate would decrease from 43 to 32 with an 80% CRC screening rate by 2018. Thus, the relative effect of the "80% by 2018" goal would be a 1% decrease in the CRC mortality rate by 2014, a decrease of 19% in 2020, and a decrease of 33% in 2030 ([Fig. 1](#fig01){ref-type="fig"} *Bottom*). This would translate to 21,000 averted cancer deaths per year by 2030, and a total of 203,000 averted deaths from 2013 through 2030 (Table [1](#tbl1){ref-type="table"}).

DISCUSSION
==========

We used microsimulation modeling to estimate the potential US public health impact of achieving the NCCR goal to increase CRC screening rates from \<60% in 2013 to 80% by 2018. The results of the current study suggest that achieving this goal may produce a reduction of 22% in CRC incidence rates and 33% in CRC mortality rates by 2030, which translates to approximately 280,000 averted new cases and 200,000 averted deaths from 2013 through 2030.

The 20% increase in CRC screening uptake from 60% to 80% has a projected high impact on CRC mortality (reduction of 33%). This 33% matches well with our recent estimate that the majority of current CRC mortality (60%) is attributable to nonuse of screening.[@b7] The increase in screening uptake from 60% to 80% decreases the number of underscreened individuals by approximately 50% and consequently reduces overall CRC mortality by roughly one-half the "population attributable fraction."

Within the underscreened population, the impact of the goal of "80% by 2018" will be larger than the overall reductions in incidence and mortality of 20% to 30% for the population because the majority of avoidable cases and deaths occur within the 40% of the population that is underscreened. Underscreened individuals tend to have lower educational levels and income and to lack health insurance.[@b23] Thus, a desirable effect of achieving a CRC screening rate of 80% by 2018 is the potential to reduce CRC health disparities in the United States, which is an important Healthy People 2020 objective.[@b24]

To our knowledge, no prior study has estimated the public health benefits of the goal of "80% by 2018." Several studies have estimated the potential contribution of screening to decreases in CRC incidence and mortality in the United States.[@b3],[@b4],[@b25],[@b26] The current study estimates of screening benefits appear to be somewhat smaller than noted by Ladabaum and Song[@b25] and larger than those from Edwards et al[@b3] and Yang et al.[@b4] This is likely due to different study designs or periods, and differences in assumptions regarding the effectiveness of colonoscopy screening. For colonoscopy, the effectiveness of screening is less well established than for other recommended screening tests due to the absence of evidence from randomized controlled trials. The effectiveness of endoscopy screening in the MISCAN-COLON model was recently increased based on the outcomes of the UK flexible sigmoidoscopy study.[@b27] This change explains the slightly higher impact of increasing screening uptake in this study compared with earlier studies.[@b3],[@b26] We evaluated a more conservative assumption for colonoscopy efficacy in which colonoscopy sensitivity for small adenomas was decreased by 50%; this decreased the impact of a CRC screening rate of 80% by 2018 on CRC incidence, but did not appear to substantively influence the mortality benefits (data not shown).

There are some limitations to the current study. First, we evaluated only 1 of 2 possible ways to increase screening rates in the United States, namely by expanding screening to previously unscreened individuals. An alternative way is to reduce the number of individuals who have been screened but not according to screening recommendations. In the latest NHIS data from 2013, the percentage of the population that ever underwent CRC screening, but not within the recommended intervals, was 7.4%.[@b5] Thus, in a strategy of encouraging both higher guideline adherence in previously screened individuals and the participation of previously unscreened individuals, the former approach could contribute approximately one-third (7.4%) to the overall targeted increase of 22% in screening rates. This may lead to a somewhat lower public health impact for the "80% by 2018" goal than we found because the impact of screening is lower in previously screened individuals compared with unscreened individuals.

Second, we assumed that the percentage of endoscopy versus fecal-based examinations and its quality remained the same in the population when screening uptake was increased, whereas higher uptake of fecal immunochemical testing or other stool-based tests may be needed to achieve the ideal of an 80% screening rate.[@b28],[@b29] A higher percentage of stool-based tests than was modeled may affect the projected benefits of increased screening uptake, although modeling analyses have demonstrated that the potential benefit of 10-year colonoscopy and annual fecal immunochemical testing may be comparable.[@b9] Colonoscopy quality is known to vary widely among providers and is highly correlated with disease outcomes.[@b30] If expanding screening, in part, was achieved through examiners with lower detection rates, then the benefits may be less than projected.

Finally, there may be CRC disparities between screened and underscreened populations beyond those attributable to screening.[@b31] If the background CRC risk in the underscreened population is higher and/or CRC survival is poorer, the impact of reaching an 80% screening rate by 2018 may be even larger.

The outcomes of the current study were confined to CRC incidence and mortality in the population, and did not include years of life lost to CRC, costs, and potential harms of screening. Previous analyses have indicated that CRC screening is likely highly cost-effective,[@b11],[@b32] and may even be cost-saving,[@b33] making increasing screening not only desirable from a perspective of cancer control but also from a financial perspective. However, these analyses usually do not consider potential overuse of screening and surveillance,[@b34] program costs,[@b35] and especially resources needed to bring in the individuals to reach a goal of 80% uptake of screening.

There are many barriers to increasing CRC screening uptake in the United States, only some of which are the target of health care reforms under the Patient Protection and Affordable Care Act.[@b36],[@b37] Substantial coordinated effort is needed to achieve the goal of an 80% CRC screening rate by 2018 in the United States. The results of the current study indicate that such investments may be well rewarded with long-term reductions in CRC incidence and mortality rates of 22% and 33%, respectively, and the avoidance of 280,000 new CRC cases and 200,000 CRC deaths in \<20 years.
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[^1]: See editorial on pages 2127-8, this issue.
